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Workers  in  the  pharmaceutical  industry  can  potentially  be  exposed  to airborne  dusts  and  powders  that
can contain  potent  active  pharmaceutical  ingredients  (API).  Occupational  hygienists  and  health  and  safety
professionals  need  to assess  and  ultimately  minimise  such  inhalation  and  dermal  exposure  risks.  Contain-
ment  of dusts  at  source  is the  ﬁrst  line of defence  but the  performance  of  such technologies  needs  to be
veriﬁed,  for  which  purpose  the  good  practice  guide:  assessing  the  particulate  containment  performance  of
pharmaceutical  equipment,  produced  by the  International  Society  for Pharmaceutical  Engineering  (ISPE),
is a  widely  used  reference  document.  This  guide  recommends  the  use  of  surrogate  powders  that  can  be
used to challenge  the  performance  of such  containment  systems.  Materials  such  as lactose  and  mannitol
are  recommended  as  their  physical  properties  (adhesion,  compactability,  dustiness,  ﬂow characteristicson chromatography
urrogates
and  particle  sizes)  mimic  those  of  API-containing  materials  typically  handled.  Furthermore  they  are  safe
materials  to use,  are  available  in  high  purity  and  can  be  procured  at a reasonable  cost.  The  aim of  this
work  was  to develop  and  validate  a sensitive  ion-chromatography  based  analytical  procedure  for  the
determination  of  surrogate  powders  collected  on  ﬁlter samples  so  as  to meet  analytical  requirements  set
out in this  ISPE  guide.
Crown  Copyright  ©  2014  Published  by Elsevier  B.V.  This  is an  open  access  article  under  the  CC. Introduction
Workers in the pharmaceutical industry can be exposed to
irborne dusts and powders that may  contain potent active phar-
aceutical ingredients (API). Occupational hygienists and health
nd safety professionals need to assess and ultimately minimise
uch inhalation and dermal exposure risks. Containment of dusts
t source is the ﬁrst line of defence but the performance of such
echnologies needs to be veriﬁed, for which purpose the ISPE good
ractice guide: assessing the particulate containment performance
f pharmaceutical equipment,  and now in its second edition is a
idely used reference [1]. This document provides guidance and
onsistent methodologies for evaluating the particle containment
particulate emissions) of pharmaceutical equipment and systems.
In this guide the use of surrogate powders, e.g. mannitol, to chal-
enge the performance of containment systems is recommended as
∗ Corresponding author. Tel.: +44 01298 218560.
E-mail address: owen.butler@hsl.gsi.gov.uk (O. Butler).
ttp://dx.doi.org/10.1016/j.jpba.2014.10.006
731-7085/Crown Copyright © 2014 Published by Elsevier B.V. This is an open 
icenses/by-nc-nd/3.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
their physical properties such as: adhesion, compactability, dusti-
ness, ﬂow characteristics and particle sizes often mimic  those of
API containing powders typically handled. They are safe materials
to use, are available in high purity and can be procured at a reason-
able cost. From an analytical viewpoint, being water soluble, they
are relatively easy to handle in the laboratory.
This challenge function involves introducing a known quantity
of a surrogate powder into a containment system and verifying its
performance by ascertaining the extent of loss of material into the
wider working environment, i.e. the fraction of surrogate powder
that escapes from the containment system. By measuring the levels
of surrogate material in air, through ﬁlter sampling and subsequent
laboratory analysis, the extent of loss can be quantiﬁed and hence
an estimation of the containment efﬁciency made. Similarly, assess-
ment can be made on dusts sedimented on work surfaces through
swabbing and subsequent analysis. A useful overview of contain-
ment testing for pharmaceutical equipment performance has been
described by Petroka [2].
The aim of this paper is to describe our approach to the devel-
opment and validation of a sensitive analytical procedure for
access article under the CC BY-NC-ND license (http://creativecommons.org/
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2.3. Validation strategy
The ISPE guide [1] does not provide detail on how to validate an
analytical method for the determination of surrogate analytes. For
Table 1
IC-PAD instrument conditions.
Instrument Dionex DX-500
Autosampler Dionex AS50
Pump Dionex IP25
Column oven Dionex AS50
Detector Dionex EC50
Analytical column Dionex MA1 4 mm × 250 mm
Guard column Dionex MA1 4 mm × 50 mm
Column temperature 40 ◦C
Eluent 480 mM NaOH, carbonate freeFig. 1. Calibration plot for M
he determination of mannitol, sorbitol and glucose surrogates
ollected on air ﬁlter samples. The approach described is also
menable to swab samples although this not reported here. This
ethodology involves leaching sampling media in water, ﬁltration
f the resultant solution and analysis using an ion chromatography
IC) system equipped with a pulsed amperometric detector (PAD).
his work builds upon earlier HSL work in which an IC-PAD method
or the determination of lactose [3] was developed in support of
ecommendations in the ﬁrst edition of the ISPE guide [1].
. Materials and methods
.1. Instrumental considerations
Initially it was assumed that the method developed for lactose
ould be extended to encompass a number of additional surro-
ate materials recommended now for inclusion in this revised ISPE
uide [1]. This original method used a Dionex PA20 5 m column
3 mm × 150 mm with a 3 mm × 50 mm guard) and a 150 mM NaOH
luent [3]. Modifying this method, by varying the eluent concen-
ration, did not produce the desired result of resolving the selected
lucose, fructose, lactose, mannitol, sorbitol and sucrose surro-
ates from each other. An alternative approach using a Dionex
A1  4 mm × 250 mm column and 480 mM NaOH eluent was then
xamined [4]. Here, mannitol and sorbitol separated with good
esolution but glucose and fructose peaks were found to co-elute.
urthermore the retention times for lactose and sucrose were too
ong, with a total sample run-time of ca. 45 min.
As gradient elution capability was not available at the Health
nd Safety Laboratory, it was decided that the existing method for
actose would be retained (sample run time of ∼8 min) and the
ew method validated now only for mannitol, sorbitol and glucose
sample run time of ∼25 min). It is anticipated that future measure-
ent of surrogates would focus on the use of such substances. Inl over 0–600 ng mL−1 range.
summary the instrumental conditions presented in Table 1 were
those subsequently used for method validation purposes.
2.2. Preparation of calibration standards
Stock standard solutions, at a nominal 1000 mg  L−1, were
prepared by dissolving known masses of high purity surro-
gate materials, procured from a number of different vendors, in
deionised water. From these single compound standards, a compos-
ite stock calibration standard solution was prepared at a nominal
24 mg  L−1 from which working calibration standards and a limit of
detection (LOD) test standard were prepared (Table 2).
Calibration veriﬁcation standards were prepared in the same
manner but using starting materials from a different vendor or from
a different lot number to those used for calibration purposes.Flowrate 0.5 mL min−1
Detection technique Pulsed amperometry
Waveform Waveform A (Dionex, TN 21)
Injection volume 200 L
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Fig. 2. Chromatogram of a 24 ng mL−1 standard.
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able 2
reparation of working calibration standards.
Calibration solution Solution to be diluted 
A Mixed calibration standard solution 24 mg L−1
B  Mixed calibration standard solution 24 mg L−1
C  Mixed calibration standard solution 24 mg L−1
D  Calibration solution C 
E  Calibration solution C 
F  Calibration solution C 
LOD  test Calibration solution A 15.0 17.5 20.0 22.5 26 .0
80 ng mL−1 standard.
Volume to dilute to 50 ml  (ml) Resulting concentration (ng mL−1)
1.25 600
0.5 240
0.25 120
20 48
8 19.2
4 9.6
0.5 6
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onsistency, a four-step validation protocol, developed previously
or the lactose method [3], was used.
.3.1. Validation step 1: determination of an instrumental LOD
The instrument was initially calibrated (Figs. 1–3) and then 11
eplicates of a 6 ng mL−1 test standard sample analysed in one ana-
ytical run. An instrumental (LOD) was then calculated for each
nalyte based on 3× standard deviation of measurements made.
.3.2. Validation step 2: spiked ﬁlter recovery test
Spiked ﬁlters were prepared and analysed to ascertain the
esorption efﬁciency of the water extraction step. Eleven spiked
lters were prepared at two loadings:
a 25-mm diameter glass ﬁbre ﬁlter (Pall-Gelman GF/F) spiked
with 90 ng of each surrogate
a 25-mm diameter glass ﬁbre ﬁlter (Pall-Gelman GF/F) spiked
with 1800 ng of each surrogate
Filter samples were placed in vials and 3 ml  deionised water
dded for extraction. After 2 h of gentle agitation on an orbital
haker, ∼2 ml  solution aliquots were removed and ﬁltered into
utosampler vials using disposable 0.2 m polyethylsulfone (PES)
yringe ﬁlters.
.3.3. Validation step 3: determination of a method LOD
Method reproducibility was assessed by the analysis of spiked
lter (Section 2.3.2) at six time intervals over a period of 3
eeks. This encompasses analytical conditions one would expect
f the method were to be in regular use, e.g. eluent replacement,
reparation of new calibration standards, changes, instrument
tart-ups/shutdowns. Subsequently a method LOD was calcu-
ated for each analyte based upon 3× standard deviation of
easurements made on twelve replicates of the 90 ng spiked ﬁl-
er.
.3.4. Validation step 4: determination of sample stability
To ascertain the potential for sample loss, once extracted but
rior to analysis, in the eventuality of an instrument failure, a trun-
ated sample stability study was undertaken. Here, six replicate
airs (Section 2.3.2) were extracted, stored in capped vials, in the
ark at room temperature for 7 days, before ﬁltration and analysis.
. Results
Validation results obtained are summarised in Tables 3–6.
. Discussion
As a prerequisite in considering analytical aspects of this work
t is useful to brieﬂy summarise the air sampling requirements.
.1. Sampling considerationsThe ISPE guide [1] cites a number of air sampler designs that can
e used to collect airborne dust samples. In the US, the 25-mm and
7-mm closed-face cassette samplers are samplers of choice whilst
able 3
alidation step 1 results: determination of an instrumental LOD.
LOD test sample
(6 ng mL−1)
% mean recovery 
%  relative standard deviation 
Calculated instrumental LOD (ng mL−1) iomedical Analysis 106 (2015) 204–209 207
in the UK, the IOM sampler is widely used. Other designs such as the
UK 7-hole cassette sampler and the conical design used in Germany
are also mentioned. Generally these samplers operate at a nominal
2 L min−1 ﬂow rate. Both personal and ﬁxed location air sampling
can be performed and sampling strategies can be found in the guide.
Personal air samples are normally collected by placing the sampler
in the worker’s breathing zone so that the air sample drawn into
the device is similar to that inhaled by the worker. Fixed location
sampling can be used to identify areas within the workplace where
dust may  be emitted.
Developments in sampler technologies since the publication of
this guide in 2012 are worth noting. Firstly, the extent of par-
ticle losses to internal walls of samplers is currently of much
research interest, i.e. the fraction of dust particles which enter the
sampler device but does not end up on the ﬁlter. Here the ISPE
guide [1] correctly states that recovery of all potential material
from the sampling device should be achieved either by rinsing or
by swabbing. In the case of 25-mm and 37-mm closed-face cas-
sette samplers it is possible to undertake in situ extraction, i.e.
to add the extracting solution directly to the sampler to leach
both the ﬁlter and the internal walls of the sampler as outlined
in other methods [5]. For IOM samplers this is not possible and
the interior walls either need to be swabbed, typically using a
moistened ﬁlter of the same type used for air sampling, or to
be rinsed. It is therefore important to recognise the potential
for wall losses. In our experience, for example, we have recov-
ered substantial quantities of analyte material from sampler walls,
particularly if a non-conducting plastic sampler has been used,
i.e. due to buildup of static charging. Such ﬁndings conﬁrm ear-
lier reported losses of pharmaceutical dusts to walls of samplers
[6]. Disposable inserts to prevent losses to walls for use with
the 25-mm and 37-mm closed-face cassette samplers are now
available [7,8] ensuring that material can be recovered for anal-
ysis.
Secondly, there is a growing requirement to increase of sensitiv-
ity of air sampling methods. This can be achieved either by using a
more sensitive analytical system or by collecting more material on
the ﬁlter through the use of high volume air samplers. New sampler
designs, operating at ﬂow rate of up to 10 l min−1, are now commer-
cially available such as the GSP10 sampler [9] and a high-ﬂow rate
derivate of 37-mm closed-face cassette samplers described in the
ISPE guide [1] is also being developed [10].
4.2. Analytical considerations
The ISPE guide [1] provides guidance and consistent methodolo-
gies for evaluating the particle containment (particulate emissions)
of pharmaceutical equipment and systems and thus helps ensure
that airborne levels are controlled to levels considered accept-
able for workers handling API of high potency. In this context it
can be useful to establish an airborne threshold or target con-
centration for the control of these agents. This is deﬁned as the
containment performance target (CPT). Where possible, CPT val-
ues can be linked to an occupational exposure limit (OEL) – an
upper limit on the acceptable concentration of a hazardous sub-
stance in workplace air set and enforced by regulation – or some
Sorbitol Mannitol Glucose
86 77 77
4.4 5.5 5.9
0.7 0.8 0.8
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Table 4
Validation step 2 results: spiked ﬁlter recovery tests.
Sorbitol Mannitol Glucose
Low concentration
(90 ng)
% mean recovery 93 95 94
%  relative standard deviation 2.0 1.5 2.6
High  concentration
(1800 ng)
% mean recovery 98 98 98
%  relative standard deviation 0.7 0.3 0.3
Table 5
Validation step 3 results: determination of a method LOD.
Sorbitol Mannitol Glucose
Low concentration
(90 ng)
% mean recovery 98 99 95
%  relative standard deviation 3.8 3.5 7.4
Calculated method LOD (ng/ﬁlter) using a nominal 3 ml  ﬁlter extraction volume 7 7 14
Calculated method limit of quantiﬁcation (LOQ – ng/ﬁlter) based upon 3.3× method LOD 23 23 46
Table 6
Results from validation step 4: determination of sample stability.
Sorbitol Mannitol Glucose
Low concentration
(90 ng)
% mean recovery after 7 days 94 103 92
%  relative standard deviation 1.5 2.6 2.4
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[3] White J., McConnachie G., Forder J., Health and Safety Laboratory, ReportHigh  Concentration
(1800 ng)
% mean recovery after 7 days 
%  relative standard deviation 
raction of the OEL provided that an OEL value exists for the API in
uestion.
In the absence of compound-speciﬁc OELs, occupational expo-
ure bands (OEB) have usually been established. Here banding is a
rocess of assigning a compound to a health hazard banding (HHB)
ategory that corresponds to a range of airborne concentrations,
nd the associated control mechanisms, needed to ensure safe
andling. Such an approach is often used within the pharmaceuti-
al sector given that OELs do not often exist for newly synthesised
ompounds of a proprietary nature. These can range from HBB1
low toxicity) to HHB5 (high toxicity) with increasingly stringent
equirements for containment control. Typically when handling a
ew API, in absence of a speciﬁc OEL and detailed supporting toxi-
ological data, a default control banding of HBB4 is often employed.
A method has been developed that successfully measures sor-
itol, mannitol and glucose captured on glass ﬁbre air sampling
lters. Based upon the validation approach used, absolute instru-
ental LOD of 7, 7 and 14 ng respectively were determined. Spike
ecoveries over a range of concentrations were typically 90–110%;
ithin run and between run precision were typically <3%; extracted
est solutions were found to be stable for at least 7 days prior to
nalysis and a method LOQ was determined to be ca. 30 ng.
The ISPE guide [1] deﬁnes the measurement sensitivity as the
nalyte mass that needs to be quantiﬁable for the evaluation of
 containment system to a desired percentage of a stated CPT.
n order to determine whether the method sensitivity is suitable,
he following equation, as deﬁned in the ISPE guide [1], can be
sed:Sensitivity(ng) = (%S×CPT×1000 ng/g×Q×t)
(1000 L m−3)
where:
%S = percentage of the CPT that is desired to be quantitated/100
CPT = containment performance target (g/m3)
Q = air sampler pump ﬂow rate (L min−1)
t = sampling time (min)As an example, for a method LoQ of ca. 30 ng determined in this
ork, and applying the following conditions:
%S = 10% (acceptable value, Appendix 4, ISPE guide)100 99 93
0.4 0.6 0.8
CPT = 1 g/m3 (health hazard band 4)
Q = 2 L min−1 (nominal sampling rate for an IOM air sampler)
A minimum sampling time of 150 min  would be required to
reach the desired method sensitivity to undertake containment
assessment against this CPT value of 1 g/m3 with quantiﬁcation
to a tenth of this limit. By switching to a higher ﬂow rate sam-
pler, such as the GSP10 device, similar method sensitivity would
be achievable in a shorter sampling time of 30 min. This could
be advantageous in assessing containment performance arising
from short duration task speciﬁc workplace activities that can be
extremely dusty, e.g. ﬁlling bags with powders.
5. Conclusion
An IC-PAD method has been developed that successfully meas-
ures sorbitol, mannitol and glucose captured on glass ﬁbre air
sampling ﬁlters. The method LOQ was  determined to be ca. 30 ng
which equates to a minimum air sampling time of 150 min  if a
containment assessment exercise were to be conducted against a
0.1 g/m3 CPT by collecting sample on a ﬁlter using an air sampler
operating at 2 L min−1.
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